Tozawa R - Search Results

1

Farnesoid X receptor antagonist exacerbates dyslipidemia in mice.

Amano Y, Yamakawa H, Yonemori K, Shimada M, Tozawa R. Amano Y, et al. Among authors: tozawa r. Pharmacol Rep. 2018 Feb;70(1):172-177. doi: 10.1016/j.pharep.2017.07.010. Epub 2017 Jul 15. Pharmacol Rep. 2018. PMID: 29367104

2

Effects of a farnesoid X receptor antagonist on hepatic lipid metabolism in primates.

Amano Y, Shimada M, Miura S, Adachi R, Tozawa R. Amano Y, et al. Among authors: tozawa r. Eur J Pharmacol. 2014 Jan 15;723:108-15. doi: 10.1016/j.ejphar.2013.10.048. Epub 2013 Dec 19. Eur J Pharmacol. 2014. PMID: 24361308

3

Antidyslipidemic effects of a farnesoid X receptor antagonist in primates.

Amano Y, Shimada M, Miura S, Adachi R, Tozawa R. Amano Y, et al. Among authors: tozawa r. Life Sci. 2014 Jun 13;106(1-2):25-31. doi: 10.1016/j.lfs.2014.04.019. Epub 2014 Apr 29. Life Sci. 2014. PMID: 24787893

4

Combinational effects of farnesoid X receptor antagonist and statin on plasma lipid levels and low-density lipoprotein clearance in guinea pigs.

Amano Y, Ishikawa E, Shinozawa E, Shimada M, Miura S, Adachi R, Tozawa R. Amano Y, et al. Among authors: tozawa r. Life Sci. 2014 Jul 11;108(1):7-12. doi: 10.1016/j.lfs.2014.04.029. Epub 2014 May 5. Life Sci. 2014. PMID: 24805868

5

Antidyslipidemic potential of a novel farnesoid X receptor antagonist in a hamster model of dyslipidemia: Comparative studies of other nonstatin agents.

Shinozawa E, Amano Y, Yamakawa H, Haba M, Shimada M, Tozawa R. Shinozawa E, et al. Among authors: tozawa r. Pharmacol Res Perspect. 2018 Mar 8;6(2):e00390. doi: 10.1002/prp2.390. eCollection 2018 Apr. Pharmacol Res Perspect. 2018. PMID: 29541476 Free PMC article.

6

Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia.

Amano Y, Nishimoto T, Tozawa Ri, Ishikawa E, Imura Y, Sugiyama Y. Amano Y, et al. Eur J Pharmacol. 2003 Apr 11;466(1-2):155-61. doi: 10.1016/s0014-2999(03)01549-8. Eur J Pharmacol. 2003. PMID: 12679152

7

Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.

Nishimoto T, Amano Y, Tozawa R, Ishikawa E, Imura Y, Yukimasa H, Sugiyama Y. Nishimoto T, et al. Among authors: tozawa r. Br J Pharmacol. 2003 Jul;139(5):911-8. doi: 10.1038/sj.bjp.0705332. Br J Pharmacol. 2003. PMID: 12839864 Free PMC article.

8

Non-alcoholic steatohepatitis-associated hepatic fibrosis and hepatocellular carcinoma in a combined mouse model of genetic modification and dietary challenge.

Amano Y, Shimizu F, Yasuno H, Harada A, Tsuchiya S, Isono O, Nagabukuro H, Tozawa R. Amano Y, et al. Among authors: tozawa r. Hepatol Res. 2017 Jan;47(1):103-115. doi: 10.1111/hepr.12709. Epub 2016 May 11. Hepatol Res. 2017. PMID: 26992446

9

Pharmacological evaluation of pioglitazone and candesartan cilexetil in a novel mouse model of non-alcoholic steatohepatitis, modified choline-deficient, amino acid-defined diet fed low-density lipoprotein receptor knockout mice.

Tsuchiya S, Amano Y, Isono O, Imai M, Shimizu F, Asada M, Imai S, Harada A, Yasuhara Y, Tozawa R, Nagabukuro H. Tsuchiya S, et al. Among authors: tozawa r. Hepatol Res. 2017 May;47(6):584-592. doi: 10.1111/hepr.12773. Epub 2016 Aug 17. Hepatol Res. 2017. PMID: 27421062

10

Role of neuromedin U in accelerating of non-alcoholic steatohepatitis in mice.

Teranishi H, Hayashi M, Higa R, Mori K, Miyazawa T, Hino J, Amano Y, Tozawa R, Ida T, Hanada T, Miyazato M, Hanada R, Kangawa K, Nakao K. Teranishi H, et al. Among authors: tozawa r. Peptides. 2018 Jan;99:134-141. doi: 10.1016/j.peptides.2017.09.011. Epub 2017 Oct 7. Peptides. 2018. PMID: 29017855

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page